FIELD: chemistry.
SUBSTANCE: group of inventions relates to a recombinant yeast cell suitable for the production of polylactic acid (hereinafter – PLA), and its use. A recombinant yeast cell suitable for the production of PLA is proposed, containing and expressing a gene encoding lactyl-CoA-synthase and a gene encoding polyhydroxyalkanoate synthase (hereinafter – PHA) (PhaCp), additionally containing a peroxisomal targeted sequence (PTS). Lactyl-CoA-synthase is selected from a group consisting of CoA transferase, propionyl-CoA transferase (Pctp) or CoA ligase. At least one activity of lactic acid oxidoreductase is inactivated in the cell, preferably a gene encoding lactic acid dehydrogenase is inactivated, more preferably a gene encoding D-lactic acid dehydrogenase is inactivated. A recombinant yeast cell is designed for the expression of lactyl-CoA-synthase in cytosol and for the expression of PHA synthase in peroxisome of the specified cell. A method for producing PLA using the specified cell, enzymatic broth for producing PLA containing the specified cell are also proposed.
EFFECT: group of inventions provides the production of high amounts of PLA.
13 cl, 10 dwg, 5 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODIES TO BTN3A AND THEIR USE IN THE TREATMENT OF CANCER OR INFECTIOUS DISEASES | 2019 |
|
RU2800726C2 |
VARIANTS OF ACID ALPHA-GLUCOSIDASE AND THEIR USE | 2017 |
|
RU2780410C2 |
IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
BTN2-SPECIFIC ANTIBODIES AND USE THEREOF | 2020 |
|
RU2821703C2 |
CANCER-RELATED IMMUNOSUPPRESSION INHIBITOR | 2018 |
|
RU2805232C2 |
TREATMENT OF ABNORMAL VISCERAL FAT DEPOSITION WITH FIBROBLAST GROWTH FACTOR 3 (sFGFR3) SOLUBLE POLYPEPTIDES | 2018 |
|
RU2794170C2 |
POLYPEPTIDES THAT ARE SOLUBLE RECEPTORS OF FIBROBLAST GROWTH FACTOR 3 (sFGFR3), AND WAYS OF THEIR APPLICATION | 2017 |
|
RU2751483C2 |
GENE THERAPY OF HYPOPHOSPHATEMIC DISEASES ASSOCIATED WITH FIBROBLAST GROWTH FACTOR 23 | 2020 |
|
RU2815545C2 |
USE OF THE ANTI-O-ACETYLATED GANGLIOSIDE GD2 ANTIBODY FOR IMPROVING THE THERAPEUTIC POTENTIAL OF DRUGS | 2017 |
|
RU2771173C2 |
ISOLATED HUMAN CD45RC ANTIBODY, NUCLEIC ACID, EXPRESSION VECTOR, CELL, PHARMACEUTICAL COMPOSITION, USE THEREOF, IN VITRO METHOD OF DETECTING hCD45RC | 2019 |
|
RU2826421C2 |
Authors
Dates
2021-10-26—Published
2016-12-15—Filed